the aid library

LIST OPTIONS

Filter

3587

Sort by:

Direction:

Download (98)

View PDF (119)

Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance, 28 January 2021
recommended

World Health Organization WHO (2021) C_WHO

The latest update (28 January 2021) includes the following addition and revision: biosafety aspects for working with antigen-detecting rapid diagnostic test; handling new variants of SARS-CoV-2 in the laboratory; updated assay decontamination before disposal; personal protectiv... more

Download (118)

View PDF (142)

Guidance for SARS-CoV-2 samples selection for genomic characterization and surveillance

Pan American Health Organisation PAHO (2021) C_WHO

Genomic sequencing has been an essential tool in generating virological data, driving the laboratory response, and better understanding the dispersal and evolutionary patterns of SARS-CoV-2. In addition to the characterization of the global circulation patterns, early detection of SARS-CoV-2 variant... more

Download (111)

View PDF (143)

Orientaciones sobre la bioseguridad en el laboratorio relacionada con la COVID-19
recommended

Organización Mundial de la Salud OMS (2021) C_WHO

Download (95)

View PDF (116)

Практическое руководство по биологической безопасности в лабораторных условиях в связи с коронавирусной инфекцией (COVID-19)
recommended

World Health Organization WHO (2021) C_WHO

Download (269)

View PDF (292)

Refugee and migrant health: Global Competency Standards for health workers

World Health Organization WHO (2021) C_WHO

This Global Competency Standards sets the benchmark for the health workforce in providing equality of care to refugees and migrants. Refugee and migrant populations are highly diverse, with significant variation in life experiences, health needs and access to health care. The standards described out... more

Download (72)

View PDF (132)

Containment strategies: lessons from early COVID-19 responses in five African countries

World Health Organization WHO, Regional Office of Africa; AHOP WHO Regional Office for Africa (2021) C_WHO

The number of COVID-19 cases is on the rise again, with South Africa nearing half of all confirmed cases in the WHO African Region. Threats of new variants loom and low vaccination coverage raises questions on the future of the response to COVID-19. Prevention remains the key strategy in most sub-Sa... more

Download (71)

View PDF (118)

Stratégies d’endiguement : enseignements tirés de la première riposte à la COVID-19 dans cinq pays africains

AHOP WHO Regional Office for Africa (2021) CC

Le nombre de cas de COVID-19 augmente à nouveau, l’Afrique du Sud comptant pour près de la moitié de tous les cas confirmés de la Région africaine de l’OMS. La menace de nouveaux variants plane, et la faible couverture vaccinale soulève des questions concernant les mesures qui devront êtr... more

Download (92)

View PDF (132)

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that policies can be tailored to different population groups. ... more

Download (136)

View PDF (166)

Covid-19 Test to Treat Guidelines
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t... more

Download (88)

View PDF (435)

The global distribution of lymphatic filariasis, 2000–2018: a geospatial analysis

The Lancet Global Health (2020) C1

Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to elimina... more

Download (79)

View PDF (430)

Modelling historical changes in the force-of-infection of Chagas disease to inform control and elimination programmes: application in Colombia

Cucunubá, Z.; Nouvellet, P.; Conteh, L. et al. BMJ Global Health (2022) CC

WHO's 2020 milestones for Chagas disease include having all endemic Latin American countries certified with no intradomiciliary Trypanosoma cruzi transmission, and infected patients under care. Evaluating the variation in historical exposure to infection is crucial for assessing progress and for und... more

Download (59)

View PDF (637)

Rabies around the World

Center for Disease Control and Prevention CDC (2020) CC

Each year, rabies causes approximately 59,000 deaths worldwide. Despite evidence that control of dog rabies through animal vaccination programs and elimination of stray dogs can reduce the incidence of human rabies, dog rabies remains common in many countries and exposure to rabid dogs is still the ... more

Download (90)

View PDF (128)

Compendium of Animal Rabies Prevention and Control, 2016

Brown C.M., Slavinski S., Ettestad P. et al National Association of State Public Health Veterinarians Compendium of Animal Rabies Prevention and Control Committee (2016) C2

Rabies is a fatal viral zoonosis and serious public health problem.1 All mammals are believed to be susceptible to the disease, and for the purposes of this document, use of the term animal refers to mammals. The disease is an acute, progressive encephalitis caused by viruses in the genus Lyssavirus... more

Download (129)

View PDF (186)

World Urbanization Prospects. The 2018 Revision

United nations. Department of Economic and Social Affairs (2019) CC

This report presents the results of the official United Nations estimates and projections of urban and rural populations for 233 countries and areas of the world and for close to 1,900 urban settlements with 300,000 inhabitants or more in 2018, as published in World Urbanization Prospects: The 2018 ... more

Download (108)

View PDF (369)

Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries

Global Burden of Disease Health Financing Collaborator Network Lancet (2017) C1

Background: The amount of resources, particularly prepaid resources, available for health can affect access to health care and health outcomes. Although health spending tends to increase with economic development, tremendous variation exists among health financing systems. Estimates of future spendi... more

Download (47)

View PDF (72)

ACT-Accelerator Prioritized Strategy & Budget for 2021

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2021) CC

In 2021 ACT-Accelerator will intensify its drive for equity and scale in the delivery of essential COVID-19 tools, while managing emerging viral risks. To address these major shifts and maintain momentum, ACT-Accelerator has defined four strategic priorities for 2021: Rapidly scale up the delivery o... more

Download (111)

View PDF (110)

Working Paper 46 - Aid, China, and Growth: Evidence from a New Global Development Finance Dataset

Dreher, A.; A. Fuchs; B. Parks et al. AidData at William & Mary (2017) CC

This paper introduces a new dataset of official financing—including foreign aid and other forms of concessional and non-concessional state financing—from China to 138 countries between 2000 and 2014. We use these data to investigate whether and to what extent Chinese aid affects economic growth ... more

Download (102)

View PDF (384)

Donor Funding for Newborn Survival: An Analysis of Donor-Reported Data, 2002–2010

Pitt1, C.; J. E. Lawn; M. Ranganathan et al. PLoS Med (2012) CC

Background:Neonatal mortality accounts for 43% of global under-five deaths and is decreasing more slowly than maternal or child mortality. Donor funding has increased for maternal, newborn, and child health (MNCH), but no analysis to date has disaggregated aid for newborns. We evaluated if and how a... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (27)

View PDF (18)

Annual Report: Global Polio Eradication Initiative

World Health Organisation (WHO) (2024) CC

The key to a lasting world free of all forms of poliovirus lies in rapidly interrupting all remaining endemic transmission of WPV in the endemic areas of Pakistan and Afghanistan. This is the only way to ensure that such strains do not re-emerge globally through international spread. It lays the cor... more

Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance, 28 January 2021 recommended

Orientaciones sobre la bioseguridad en el laboratorio relacionada con la COVID-19 recommended

Практическое руководство по биологической безопасности в лабораторных условиях в связи с коронавирусной инфекцией (COVID-19) recommended

Covid-19 Test to Treat Guidelines recommended

Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance, 28 January 2021
recommended

Orientaciones sobre la bioseguridad en el laboratorio relacionada con la COVID-19
recommended

Практическое руководство по биологической безопасности в лабораторных условиях в связи с коронавирусной инфекцией (COVID-19)
recommended

Covid-19 Test to Treat Guidelines
recommended